Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $28
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $18 to $28.
Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $18 to $28.